Literature DB >> 2472227

Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

V I Avramis1, W C Powell, R A Mecum.   

Abstract

5,6-Dihydro-5-azacytidine (DHAC) is a hydrolytically stable analog of 5-azacytidine (5-aza-C) that has antileukemic activity against experimental leukemias and, like 5-aza-C, causes DNA hypomethylation. We report the cellular metabolism of DHAC and its incorporation into nucleic acids in the CCRF/CEM/O and deoxycytidine kinase mutant CCRF/CEM/dCk(-) human lymphoid cell lines. The cells were incubated with their respective IC50 concentrations for 24 h, then aliquot samples were removed at predetermined intervals and extracted for nucleotides. The acid-soluble extracts of the cells were assayed on HPLC for nucleotides of DHAC. The major anabolite of [3H]DHAC, [3H]DHACTP, peaked at 110.3 +/- 30.7 microM in CEM/O and at 96.3 +/- 41.9 microM in CEM/dCk(-) cells at 9 and 12 h, respectively. The intracellular concentrations of the deoxyribonucleoside triphosphate, [3H]DHAdCTP, peaked at 13.5 +/- 7.7 microM at 4 h in CEM/O and at 80.8 +/- 13.8 microM at 12 h, a 6-fold greater cellular concentration, in the dCk mutant cell line. The amount of DHAC anabolites incorporated into CEM/O nucleic acids reached a plateau in RNA at 552.6 +/- 7.8 pmol/10(7) cells and in DNA at 64.55 +/- 10.0 pmol/10(7) cells. In CEM/dCk(-) cells, DHAC anabolites reached a plateau in RNA and DNA at 4,256.3 +/- 631.0 and 395.5 +/- 145.4 pmol/10(7) cells, respectively. Thus, with equitoxic treatments of DHAC, the incorporation of its analog anabolites into RNA and DNA was 8- and 6-fold greater in CEM/dCk(-) cells. DNA methylation levels were depressed equally despite a 6-fold greater incorporation of the analog in DNA in the CEM/dCk(-) cells indicating that hypomethylation may be saturated after DHAC treatment. The DNA methylation levels reached a nadir of 0.19% and 0.20% methyl-C (percentage of methylation) in the two cell lines at 6 and 12 h after the beginning of drug treatment and remained relatively constant for the duration of the 24-h treatment. A curve-linear relationship was obtained between the DNA methylation levels in both cell lines and the amounts of DHAC anabolite incorporated into DNA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472227     DOI: 10.1007/bf00300235

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

Review 1.  Advances in the treatment of acute myelogenous leukemia.

Authors:  R P Gale
Journal:  N Engl J Med       Date:  1979-05-24       Impact factor: 91.245

2.  Treatment of acute leukemia with 5-azacytidine (NSC-102816).

Authors:  K B McCredie; G P Bodey; M A Burgess; J U Gutterman; V Rodriguez; M P Sullivan; E J Freireich
Journal:  Cancer Chemother Rep       Date:  1973 Sep-Oct

3.  Dihydro-5-azacytidine hydrochloride, a biologically active and chemically stable analog of 5-azacytidine.

Authors:  J A Beisler; M M Abbasi; J S Driscoll
Journal:  Cancer Treat Rep       Date:  1976-11

4.  Drug control of Ara-C-resistant tumor cells.

Authors:  F M Schabel; H E Skipper; M W Trader; R W Brockman; W R Laster; T H Corbett; D P Griswold
Journal:  Med Pediatr Oncol       Date:  1982

5.  Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions.

Authors:  R E Notari; J L DeYoung
Journal:  J Pharm Sci       Date:  1975-07       Impact factor: 3.534

6.  Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.

Authors:  V I Avramis; R Biener; M Krailo; J Finklestein; L Ettinger; M Willoughby; S E Siegel; J S Holcenberg
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

7.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

8.  Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice.

Authors:  W C Powell; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  Establishment of cross-resistance profiles for new agents.

Authors:  F M Schabel; H E Skipper; M W Trader; W R Laster; D P Griswold; T H Corbett
Journal:  Cancer Treat Rep       Date:  1983-10

10.  Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.

Authors:  B E Antonsson; V I Avramis; J Nyce; J S Holcenberg
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

View more
  2 in total

1.  Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.

Authors:  Marcelo L Ribeiro; Diana Reyes-Garau; Marc Armengol; Miranda Fernández-Serrano; Gaël Roué
Journal:  Front Genet       Date:  2019-10-16       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.